Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II)
Abstract
Aim. To study efficacy and safety of propafenone (450 mg/d per os) in maintaining sinus rhythm among patients with persistent atrial fibrillation (AF).
Material and methods. The study included 200 patients with persistent AF, aged 39-68 (mean age 56.4±4.2 years), from 10 Russian regions. For AF paroxysm prevention, all patients received propafenone (Propanorm, 450 mg per os, 3 times per day) for 9 months.
Results. Propafenone (450 mg/d) restored sinus rhythm in 148 patients (74%) after one month of treatment, in 122 (61%) after 3 months, and in 90 (45%) after 9 months. Propafenone was effective and well tolerated: during 9-month therapy, only 8 patients (4%) complained of dyspepsia, which regressed without additional therapy or treatment discontinuation. Arrhythmogenic effects of propafenone were not registered. In 7 patients (3.5%), PQ interval increased significantly, by 18% comparing to baseline, but the parameter stayed in the normal range. Moderate increase of QT interval (+28%), without being over 460 ms, was observed in 8 patients (4%), and did not require therapy discontinuation.
Conclusion. According to the results of open, multi-center study “PROMETEY”, propafenone (450 mg/d per os) was effective and safe for maintaining sinus rhythm in patients with persistent AF. In patients with normal left ventricular ejection fraction, propafenone did not affect inotropic myocardial function.
About the Authors
I. G. Fomina
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
A. I. Tarzimanova
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
A. V. Vetluzhsky
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
A. A. Abramova
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
References
1. Боровков Н.Н., Мазалков К.В., Советская Е.В. и др. Эффективность пропафенона в купировании пароксизмов фибрилляции предсердий. РКЖ 2003; 5(43): 65-7.
2. Захар А., Антонченко И.В., Борисова Е.В. и др. Клиническая эффективность и безопасность купирования пароксизмов фибрилляции предсердий пропафеноном. РКЖ 2003; 4: 59-62.
3. Миллер О.Н., Бондарева З.Г., Пирогова Л.А. Пропафенон в профилактике пароксизмов фибрилляции предсердий у больных с некоронарогенными заболеваниями миокарда. РКЖ 2002; 3(35): 41-5.
4. Татарский Б.А. Протекторный эффект пропафенона при пароксизмальных реципрокных атриовентрикулярных тахикардиях. РКЖ 2004; 1(45): 45-53.
5. Скибицкий В.В., Кудряшов Е.А., Спиропулос Н.А. Изучение эффективности пропафенона при пароксизмальной фибрилляции предсердий. РКЖ 2004; 6: 68-70.
6. Dogan A, Ergene O, Nazli C. Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. Acta Cardiol 2004; 59(3): 255-61.
7. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J 2001; 22: 1852-923.
8. Kochiadakis GE, Igoumenidis NE, Hamilos MI, et al. Longterm maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest 2004; 125(2): 377-83.
9. Bryson HM, Palmer KJ. Propafenone: a reappraiser of its pharmacology, pharmacjkinetics and therapeutic use in cardiac arrhythmias. Drugs 1993; 45: 85-130.
Review
For citations:
Fomina I.G., Tarzimanova A.I., Vetluzhsky A.V., Abramova A.A. Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation (part II). Cardiovascular Therapy and Prevention. 2005;4(5):62-65. (In Russ.)
Views:
1581
Email this article 
